title: Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study.
abstract: BACKGROUND
  The PROLONG study showed that patients with venous thromboembolism who had qualitatively abnormal results in a D-dimer assay (Clearview Simplify D-dimer) after discontinuation of vitamin K antagonism benefit from resumption of treatment with vitamin K antagonism. The objective of this study was to evaluate the possible advantage of using quantitative D-dimer assays.
  
  
  METHODS
  VIDAS D-dimer Exclusion (bioMerieux), Innovance D-DIMER (Dade Behring), HemosIL D-dimer HS (Instrumentation Laboratory) and STA Liatest D-dimer (Diagnostica Stago) assays were performed in plasma aliquots sampled 30+/-10 days after cessation of vitamin K antagonism in 321 patients enrolled in the PROLONG study.
  
  
  RESULTS
  During the follow-up without vitamin K antagonism, 25 patients had recurrent venous thromboembolism. The cut-off levels of the quantitative assays giving results most comparable with those of the qualitative test were: VIDAS = 800 ng/mL; Innovance = 800 ng/mL; HemosIL HS = 300 ng/mL; STA Liatest = 700 ng/mL. When the effect of the patients' age (< or = 70 vs. >70 years) was analyzed, it was found that only in younger patients was the rate of recurrence of venous thromboembolism significantly higher in patients with abnormal D-dimer levels. However, using the quantitative assays and age-specific cut-off levels it was possible to determine statistically significant hazard ratios also in elderly patients (VIDAS = 600 and 1200 ng/mL, Innovance = 500 and 900 ng/mL, HemosIL HS = 250 and 450 ng/mL, STA Liatest = 700 and 1000 ng/mL, in patients aged < or = 70 and >70 years, respectively).
  
  
  CONCLUSIONS
  Quantitative D-dimer assays may provide information useful for evaluating the individual risk of recurrent venous thromboembolism. They seem particularly advantageous since they allow the selection of different cut-off levels according to the age or other characteristics of the patients.
authors.affiliation: Department of Angiology and Blood Coagulation "Marino Golinelli", University Hospital S. Orsola-Malpighi, via Albertoni 15, 40138 Bologna, Italy. cristina.legnani@aosp.bo.it
authors.forename: Cristina
authors.initials: C
authors.lastname: Legnani
authors.forename: Gualtiero
authors.initials: G
authors.lastname: Palareti
authors.forename: Benilde
authors.initials: B
authors.lastname: Cosmi
authors.forename: Michela
authors.initials: M
authors.lastname: Cini
authors.forename: Alberto
authors.initials: A
authors.lastname: Tosetto
authors.forename: Armando
authors.initials: A
authors.lastname: Tripodi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001774:Blood Chemical Analysis / Q000379:methods* / Q000592:standards*; D002986:Clinical Trials as Topic; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis* / Q000096:biosynthesis*; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012306:Risk; D054556:Venous Thromboembolism / Q000097:blood* / Q000175:diagnosis*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D014812:Vitamin K